Evidence map›Paper›PMID 34495772›Full record

ArticleAIDS care2022

PrEP for key populations: results from the first PrEP demonstration project in the Democratic Republic of the Congo.

Julie Franks, Chloe Teasdale, Halli Olsen, Chunhui Wang, Nadine Mushimebele, Richted Tenda Mazala, Tania Tchissambou, Faustin Malele Bazola, Trista Bingham, Gaston Djomand and 4 more

Abstract read
In one paragraph

Article in AIDS care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Julie FranksICAP at Columbia University, New York, NY, USA.ORCID 0000-0001-6329-2301
Chloe TeasdaleICAP at Columbia University, New York, NY, USA.
Halli OlsenICAP at Columbia University, New York, NY, USA.
Chunhui WangICAP at Columbia University, New York, NY, USA.
Nadine MushimebeleICAP at Columbia University, New York, NY, USA.
Richted Tenda MazalaICAP at Columbia University, New York, NY, USA.
Tania TchissambouICAP at Columbia University, New York, NY, USA.
Faustin Malele BazolaICAP at Columbia University, New York, NY, USA.
Trista BinghamDivision of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Gaston DjomandDivision of Global HIV & TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Elie MukindaDemocratic Republic of the Congo Centers for Disease Control and Prevention, Kinshasa, Democratic Republic of the Congo.
Raimi EwetolaDemocratic Republic of the Congo Centers for Disease Control and Prevention, Kinshasa, Democratic Republic of the Congo.
Elaine AbramsICAP at Columbia University, New York, NY, USA.
William ReidyICAP at Columbia University, New York, NY, USA.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

Oral pre-exposure prophylaxis (PrEP) is recommended for persons at substantial risk for HIV, including female sex workers (FSW), men who have sex with men (MSM), people who inject drugs (PWID), and transgender women (TGW). We report on a PrEP demonstration project at seven clinics in the Democratic Republic of the Congo. Routinely collected data were abstracted to assess PrEP uptake, scheduled visit attendance, and self-reported adherence. Between February and May 2018, 469 eligible clients were offered daily oral PrEP; 75.1% accepted: 78.7% FSW, 20.5% MSM, and 0.9% TGW. Two percent also identified as PWID. Attendance was 64.5% at one-month visits; 82.1% at three-month visits; and among 47.7% of clients who initiated PrEP at least six months before data abstraction, 85.8% at six-month visits. Among 66.3% of clients with at least one adherence assessment, 39% self-reported low adherence. Results demonstrate the acceptability of PrEP delivered in healthcare settings serving FSW, MSM, PWID, and TGW.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisSexual and Gender MinoritiesSex WorkersTransgender PersonsDemocratic Republic of the CongoFemaleHomosexuality, MaleHumansMaleAnti-HIV AgentsDemocratic Republic of Congofemale sex workersHIV preventionkey populationsmen who have sex with menpeople who inject drugsPre-exposure prophylaxis

Identifiers

PMID34495772
PMCPMC10627785

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.